AKTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.7M
+1.7%
4.6M
-70.8%
15.8M
+388.3%
3.2M
-56.4%
7.4M
R&D
2.1M
+1.5%
2.1M
+42.4%
1.5M
+34.3%
1.1M
+336.1%
249.0K
SG&A
2.6M
+1.7%
2.5M
+16.4%
2.2M
+1.3%
2.1M
+8.4%
2.0M
Operating Income
-4678000
-1.7%
-4602000
+70.8%
-15758000
-388.3%
-3227000
+56.4%
-7404000
EBITDA
-4678000
-1.7%
-4602000
-26.8%
-3628000
-12.4%
-3227000
-45.1%
-2224000
Net Income
-4843000
-0.7%
-4807000
+66.7%
-14455000
-172.8%
-5298000
+17.2%
-6400000
EPS (Basic)
$0.00
$0.00
$0.00
$0.00
$0.00
EPS (Diluted)
$0.00
$0.00
$0.00
$0.00
$0.00
Shares (Diluted)
265.9B
+85.5%
143.3B
+20.7%
118.8B
+5394.6%
2.2B
-96.7%
65.3B
Akari Therapeutics plc (0.01 USD) (AKTX) — Financials